ALOX12 deficiency is commonly observed in cancer patients, and missense mutations in ALOX12 can result in the loss of its ability to oxidize polyunsaturated fatty acids, thereby enhancing p53-induced ferroptosis 31. This evidence concerns the gene TP53 and cancer.